Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Sanofi exec tells biotechs not to scrimp on clinical trial design
It is vital for biotech companies to run the right clinical trial and not cut costs with trial design or patient recruitment, the executive said.
AstraZeneca’s Calquence approved by EC for first-line mantle cell lymphoma use
AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved by the European Commission (EC) as part o...
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy
Q1 earnings pulse check: companies tentative on pharma-specific tariffs
Whilst 2025 outlooks include cost impacts from existing tariffs, companies have not adjusted their guidance for future pharma-specific ones.
Preclinical study reveals how alcohol promotes fat buildup in liver
Cedars-Sinai investigators have discovered a signaling interaction between two proteins in cells that controls fat accumulation in the livers of laboratory mice with alcohol-associated liver disease.
Chinese regulator grants priority review for InnoCare’s solid tumour treatment
A pan-tropomyosin receptor kinase (TRK) inhibitor, zurletrectinib (ICP-723) is said to have demonstrated better safety and efficacy in a registration trial.
HHS launches $500m universal vaccines initiative
The US Department of Health and Human Services (HHS) has launched a $500m initiative to accelerate the development of universal vaccines targeting viruses with pandemic potential, including in...
FDA awards RMAT status to 4DMT diabetic macular oedema therapy
4D Molecular Therapeutics (4DMT) has received regenerative medicine advanced therapy (RMAT) designation from the US Food and Drug Administration (FDA) for 4D-150 for diabetic m...
Avutometinib Combo Shows Activity, Safety for HR+/HER2- Breast Cancer
The combination of avutometinib (VS-6766), abemaciclib (Verzenio), and fulvestrant (Faslodex) showed a manageable safety profile and early signs of efficacy in patients with ho...
FDA Clears IND Application for TROP-2 Targeting ADC in Solid Tumors
The FDA has cleared an investigational new drug (IND) application for the TROP-2 targeted antibody drug conjugate (ADC), OBI-902, to conduct a phase 1/2 study in patients with solid tu...
Scientists at the University of East Anglia (UEA) have developed a revolutionary new way
Scientists at the University of East Anglia (UEA) have developed a revolutionary new way of uncovering the 'true age' of your heart using MRI
Dimerix and Amicus to commercialise DMX-200 in US
Australian biopharmaceutical company Dimerix and Amicus Therapeutics have signed an agreement for the US commercialisation of the former’s Phase III drug candidate DMX-200.
24
25
26
27
28
29
30
31
32
